Please, Signup (Login) to subscribe or trade (demo)
Pfizer stock price
Pfizer latest news:
GSK CEO says looking at Pfizer consumer business, but not a priority
Jan 9 (Reuters) - GlaxoSmithKline's new chief
executive said on Tuesday that the British drugmaker would have
a look at Pfizer Inc's consumer products business, but
would not overpay for the asset.
Pfizer Halts Research Efforts Into Alzheimer's And Parkinson's Treatments
The pharmaceutical giant said it would be abandoning its neuroscience development programs and allocating its spending elsewhere. The move also means the company will be laying off some 300 employees.
Pfizer ends research for new Alzheimer's, Parkinson's drugs
NEW YORK, Jan 7 (Reuters) - Pfizer Inc is abandoning
research to find new drugs aimed at treating Alzheimer's and
Parkinson's disease, the U.S. pharmaceutical company announced
Sangamo Jumps on Newest Pfizer Collaboration
BRIEF-Pfizer Announces Breakthrough Therapy Designation For Avelumab In Combination With Inlyta
Pfizer Inc(PFE): * FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR AVELUMAB IN COMBINATION WITH INLYTA® IN ADVANCED RENAL CELL CARCINOMA. * PFIZER - BREAKTHROUGH THERAPY DESIGNATION IS BASED ON PRELIMINARY EVALUATION OF CLINICAL DATA FROM JAVELIN RENAL 100 STUDY Source text for Eikon: Further company coverage:
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Cancer treatments from Pfizer Inc (PFE) and Exelixis Inc (EXEL) on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients. Pfizer's Bosulif was expanded to treat newly-diagnosed adult patients with a rare, chronic form of blood cancer.
BRIEF-FDA Approves Pfizer's Bosulif To Treat A Type of Leukemia
Pfizer Inc(PFE): * U.S. FDA APPROVES PFIZERS BOSULIF® FOR THE TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA Source text for Eikon: Further company coverage:
UPDATE 1-Pfizer announces new $10 bln share buyback, hikes dividend
Dec 18 (Reuters) - Pfizer Inc said on Monday its
board had authorized a new $10 billion share repurchase program
and raised its quarterly dividend.
Pfizer announces new $10 bln share buyback, hikes dividend
Pfizer Inc(PFE) said on Monday its board had authorized a new $10 billion share repurchase program and raised its quarterly dividend. The share buyback is in addition to the $6.4 billion remaining under the company's current authorization, Pfizer said. The drugmaker hiked its first-quarter dividend to 34 cents per share from 32 cents.
Pfizer sets new $10 billion stock buyback program, bumps up dividend by 6.3%
Shares of Pfizer Inc. edged up 0.3% in midday trade Monday, after the drug giant said it authorized a new $10 billion share repurchase program, and that it will raise its quarterly cash dividend by 6.3%. Pfizer said the new buyback program is in addition to the $6.4 billion remaining under the current repurchase program. Based on current share prices and 5.96 billion shares outstanding, $16.4 billion would represent 439.7 million shares, or about 7.4% of the shares outstanding. The new dividend of 34 cents a share, up from 32 cents a share, will be payable March 1 to shareholders of record on Feb. 2. The new annual dividend rate implies a dividend yield of 3.65%, compared with the implied yield for the SPDR Health Care Select Sector ETF of 1.45%, and for the Dow Jones Industrial Average of 2.07%. Pfizer's stock has rallied 14.8% year to date, while the health care ETF has run up 21.9% and the Dow has climbed 25.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion
Pfizer Inc PFE announced that the FDA has approved a label expansion for its janus kinase JAK inhibitor Xeljanz tofacitinib for two doses 5 mg twice daily and 11 mg once daily extended release XR formulation With this latest approval Xeljanz can now be administered for
UPDATE 1-Pfizer's Xeljanz gets FDA nod as joint disease treatment
Dec 14 (Reuters) - U.S. drugmaker Pfizer Inc said on
Thursday the U.S. Food and Drug Administration (FDA) approved
two doses of its drug Xeljanz for treatment of a joint disease.
Pfizer's Xeljanz gets FDA nod as joint disease treatment
Dec 14 (Reuters) - U.S. drugmaker Pfizer Inc said on
Thursday the United States Food and Drug Administration (FDA)
approved two doses of its drug Xeljanz for the treatment of a
BRIEF-Pfizer Announces FDA Approval Of Xeljanz® And Xeljanz® Xr For Treatment Of Active Psoriatic Arthritis
* PFIZER ANNOUNCES FDA APPROVAL OF XELJANZ® (TOFACITINIB)
XELJANZ® XR FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
BRIEF-FDA Approves Pfizer's New Biosimilar To Remicade
Pfizer Inc(PFE): * FDA APPROVES NEW PFIZER BIOSIMILAR. * Pfizer Inc(PFE) - UNITED STATES FOOD AND DRUG ADMINISTRATION HAS APPROVED IXIFI AS A BIOSIMILAR TO REMICADE Source text for Eikon: Further company coverage:
Why Cellectis Is Winning Big With Its Pfizer Partnership
BRIEF-U.S. FDA Extends Action Date For Expanded Label of Pfizer's Xeljanz In Ulcerative Colitis By Three Months
Pfizer Inc(PFE): * U.S. FOOD AND DRUG ADMINISTRATION EXTENDS ACTION DATE FOR XELJANZ® SUPPLEMENTAL NEW DRUG APPLICATION IN ULCERATIVE COLITIS BY THREE MONTHS. * Pfizer Inc (PFE) - FDA HAS PROVIDED AN ANTICIPATED PRESCRIPTION DRUG USER FEE ACT DATE IN JUNE 2018.
Gene-therapy approach to hemophilia finds success in study, Spark stock surges
Spark Therapeutics Inc. stock surged Wednesday afternoon after the company announced positive results from a study of a gene-therapy approach to hemophilia. The drug, developed and tested in a collaboration with Pfizer Inc. , involves a single injection meant to help those suffering from hemophilia B, a disease that keep blood from clotting and is typically treated with regular and costly infusions. The study followed 10 adult males for 492 weeks and found that the number of episodes of bleeding decreased from an average of 11.1 a year before administration to 0.4 per year after, while infusions were reduced by 99%. The results were published in The New England Journal of Medicine on Wednesday, the companies said in a news release. Spark shares jumped as much as 9% in late trading after the announcement Wednesday, while Pfizer shares were unchanged.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Viagra goes generic: Pfizer to launch own little white pill
Pfizer launching own generic Viagra as other cheap versions are headed to US market
BRIEF-Acentrus Specialty Signs New Agreement With Pfizer Oncology
Pfizer Inc(PFE): * ACENTRUS SPECIALTY SIGNS NEW AGREEMENT WITH PFIZER ONCOLOGY. * ACENTRUS SPECIALTY SAYS SIGNED NEW AGREEMENT THAT OFFERS QUALIFIED ACENTRUS HOSPITAL AND HEALTH SYSTEM CLIENTS ACCESS TO PFIZER ONCOLOGY PRODUCTS. * ACENTRUS SPECIALTY - CONTRACT INCLUDES 5 ORAL ONCOLYTIC PRODUCTS; IBRANCE, BOSULIF, SUTENT, INLYTA AND XALKORI Source text for Eikon: Further company coverage:
Cancer Space Update: Pfizer's Bavencio Fails in Phase III
There was no major news in the cancer space this week except the failure of Pfizer Inc s PFE Bavencio in a gastric cancer study In a setback to Eisai Co Ltd ESALY National Institute of Health and Care Excellence NICE did not recommend the approval of its breast cancer drug
BRIEF-Pfizer Says Entered Into Agreement To Develop And Commercialize Cresemba In China And Asia Pacific
Pfizer Inc(PFE): * SAYS PFIZER ENTERS INTO AGREEMENT TO DEVELOP AND COMMERCIALIZE CRESEMBA IN CHINA AND ASIA PACIFIC REGION Source text for Eikon: Further company coverage:
BRIEF-Basilea Extends Existing License Agreement With Pfizer For Cresemba
BASILEA PHARMACEUTICA AG: * BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® TO CHINA AND ASIA PACIFIC. * BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED. * ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES. * WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.
BRIEF-Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women
* VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND
LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF
HIV INFECTION IN SEXUALLY ACTIVE WOMEN
Source text for Eikon:
Further company coverage:
UPDATE 1-UK gives Pfizer world's first over-the-counter Viagra approval
LONDON, Nov 28 (Reuters) - Pfizer's big-selling
erectile dysfunction drug Viagra has been given a green light
for sale without a prescription in Britain, the first country to
grant it over-the-counter status.
BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume after Pfizer exited China JV
Zhejiang Hisun Pharmaceutical Co Ltd : * SAYS SHARE TRADE TO RESUME ON NOV 29 AFTER PFIZER EXITED CHINA JOINT VENTURE WITH THE COMPANY Source text in Chinese: http://bit.ly/2iZ534b Further company coverage:
BRIEF-Merck And Pfizer Provide Update On Phase III Javelin Gastric 300 Study In Patients With Pre-Treated Advanced ...
Pfizer Inc(PFE): * MERCK AND PFIZER PROVIDE UPDATE ON PHASE III JAVELIN GASTRIC 300 STUDY IN PATIENTS WITH PRE-TREATED ADVANCED GASTRIC CANCER.
ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just two drugs -- dolutegravir and rilpivirine, both of which have been previously approved -- while other HIV regimens are typically composed of at least three drugs. This advancement could make the regimen more tolerable for the patient, according to Dr. Debra Birnkrant, director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research. Juluca is approved for individuals with HIV-1 who have been stable on a regimen for at least half a year, have no history of treatment failure and no known resistance to Juluca's individual components, ViiV said. GlaxoSmithKline shares declined 0.8% in Tuesday trade; shares have dropped nearly 10% over the last three months, compared with a 7% rise in the S&P 500 and a nearly 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
U.S. FDA expands approval for Pfizer cancer drug Sutent
The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's (PFE) cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney. Sutent was approved in 2006 for patients with gastrointestinal stromal tumors and advanced kidney cancer.
UPDATE 1-Pfizer creates chief operating officer role for Bourla
NEW YORK, Nov 13 (Reuters) - Drugmaker Pfizer Inc
has promoted Albert Bourla to the newly created post of chief
operating officer, freeing up Chief Executive Officer Ian Read
to focus more on long-term strategy and engaging with government
and industry leaders.
Philip Morris International IncPM
Philippine Long Distance Telephone CompanyPHI
Phillips 66 Partners LPPSXP
Phoenix New Media LimitedFENG
Physicians Realty TrustDOC